Microbiologic efficacy of moxifloxacin for the treatment of community- acquired pneumonia due to Chlamydia pneumoniae

International Journal of Antimicrobial Agents

Volumn 15, Issue 2, 2000, Pages 149-152

  Hammerschlag, Margaret R ^a   Roblin, Patricia M ^a  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

Chlamydia pneumoniae; Community acquired pneumonia; Moxifloxacin

Indexed keywords

CLARITHROMYCIN; MOXIFLOXACIN;

ARTICLE; CHLAMYDIASIS; CHLAMYDOPHILA PNEUMONIAE; CLINICAL TRIAL; COMMUNICABLE DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; NASOPHARYNX; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; AZA COMPOUNDS; CHLAMYDIA INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; CLARITHROMYCIN; COMMUNITY-ACQUIRED INFECTIONS; FLUOROQUINOLONES; HUMANS; INHIBITORY CONCENTRATION 50; MICROBIAL SENSITIVITY TESTS; NASOPHARYNX; PNEUMONIA, BACTERIAL; QUINOLINES;

EID: 0034116610     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(00)00157-6     Document Type: Article

References (15)

1. Grayston J.T., Campbell L.A., Kuo C.C., et al. A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR. J. Infect. Dis. 161:1990;618-625.
2. Block S.J., Hedrick J., Hammerschlag M.R., Cassell G.H., Craft C. Mycoplasma pneumoniae and Chlamydia pneumoniae in pediatric community-acquired pneumonia: comparative efficacy and safety of clarithromycin versus erythromycin ethylsuccinate. Pediatr. Infect. Dis. J. 14:1995;471-477.
3. Bartlett J.G., Breiman R.F., Mandell L.A., File T.M. Jr. Community acquired pneumonia in adults: guidelines for management. Clin. Infect. Dis. 26:1998;811-838.
4. Lipsky B.A., Tack K.J., Kuo C.C., Wang S.P., Grayston J.T. Ofloxacin treatment of Chlamydia pneumoniae (strain TWAR) lower respiratory tract infections. Am. J. Med. 89:1990;722-724.
5. Plouffe J.F., Herbert M.T., File T.M., et al. Ofloxacin versus standard therapy in treatment of community-acquired pneumonia requiring hospitalization. Antimicrob. Agents Chemother. 40:1996;1175-1179.
6. File T.M., Segreti J., Dunbar L., et al. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in the treatment of adults with community-acquired pneumonia. Antimicrob. Agents Chemother. 41:1997;1965-1972.
7. Leophonte P., Baldwin R.J.T., Pluck N. Trovafloxacin versus amoxicillin/clavulanic acid in the treatment of acute exacerbations of chronic obstructive bronchitis. Eur. J. Clin. Microbiol. Infect. Dis. 17:1998;434-440.
8. Deabate C.A., Henry D., Bensch G., et al. Sparfloxacin versus ofloxacin in the treatment of acute bacterial exacerbations of chronic bronchitis - a multicenter, double-blind, randomized, comparative study. Chest. 114:1998;120-130.
9. Roblin P.M., Dumornay W., Hammerschlag M.R. Use of HEp-2 cells for improved isolation and passage of Chlamydia pneumoniae. J. Clin. Microbiol. 30:1992;1968-1971.
10. Hammerschlag M.R., Qumei K.K., Roblin P.M. In vitro activities of azithromycin, clarithromycin, L-ofloxacin and other antibiotics against Chlamydia pneumoniae. Antimicrob. Agents Chemother. 36:1992;1573-1574.
11. Roblin P.M., Hammerschlag M.R. Microbiologic efficacy of azithromycin and susceptibility to azithromycin of isolates of Chlamydia pneumoniae from adults and children with community acquired pneumonia. Antimicrob. Agents Chemother. 42:1998;194-196.
12. Roblin P.M., Hammerschlag M.R. In vitro activity of a new 8-methoxyquinolone, BAY 12-8039, against Chlamydia pneumoniae. Antimicrob. Agents Chemother. 42:1998;951-952.
13. Roblin P.M., Kudin A., Reznik T., Hammerschlag M.R. In vitro activity of grepafloxacin and other fluoroquinolones and newer macrolides against recent clinical isolates of Chlamydia pneumoniae. Int. J. Antimicrob. Agents. 12:1999;181-184.
14. Roblin P.M., Montalban G., Hammerschlag M.R. Susceptibility to clarithromycin and erythromycin of isolates of Chlamydia pneumoniae from children with pneumonia. Antimicrob. Agents Chemother. 38:1994;1588-1589.
15. Dessus-Babus S., Bebear C.M., Charron A., Bebear C., de Barbeyae B. Sequencing of gyrase and topoisomerase IV quinolone-resistance-determining regions of Chlamydia trachomatis and characterization of quinolone-resistant mutants obtained in vitro. Antimicrob. Agents Chemother. 42:1998;2474-2481.